ArticleBiological procedures online2026
Ribosomal Protein RPL29 Promotes Hepatocellular Carcinoma Progression Through Regulation the Expression of Exosome Component 4.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThere are notable challenges in the development of effective therapeutic interventions for primary liver cancer (PLC). The role of ribosomal protein (RP) RPL29 in cancer has been rarely reported and the underlying mechanisms of RPL29 in the progression of Hepatocellular carcinoma (HCC) remain unclear.
methodsIn the present study, the expression level and prognostic value of RPL29 in patients with HCC was evaluated by bioinformatics and immunohistochemistry. Moreover, gene expression was suppressed using targeted siRNAs and enhanced through plasmids containing specific gene cDNA sequences. Subsequently, assessments of cell viability and invasive capacity were conducted. Additionally, Western blot analyses and subcutaneous xenograft models in nude mice were utilized to elucidate the potential function of RPL29 in regulating the malignant phenotype of HCC.
resultsThe expression of RPL29 was found to be significantly elevated in HCC tissues. Further investigation demonstrated that RPL29 actively promotes the proliferation and metastatic potential of HCC cells. Moreover, RPL29 was shown to enhance the expression of Exosome Component 4 (EXOSC4), thereby contributing to the progression and metastasis of HCC. Both RPL29 and EXOSC4 were markedly overexpressed in HCC tissues and were associated with poorer overall survival and disease-free survival outcomes. Notably, the overexpression of RPL29 was able to restore cell viability and invasive capabilities in HCC cells in EXOSC4 silenced cells. In addition, we conducted a screening of two small molecule drugs that specifically target EXOSC4.
conclusionThe present study demonstrated that RPL29 facilitates HCC progression by regulating the expression of EXOSC4, which provides a novel therapeutic option for patients with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.